In order to further validate these results, we employed the IL-6/JAK/STAT3 pathway inhibitors αIL-6R, Baricitinib (JAK inhibitor, Amadis Chemical) and Stattic (STAT3 Inhibitor, Sigma-Aldrich), and determined their effect on the melanoma-microglia crosstalk. Here, IL6 is linked to melanoma.